Ann Kono
Known title: DirectorCIK: 0001837209
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Cathay General Bancorp Eyes 13% Premium After Q3 Earnings Preview. The bank’s Q3 earnings preview suggests it could trade up to 13% above fair value. An upcoming Q3 2026 results announcement may confirm this view. Analysts target $65, within its 52‑week range. The stock sits near a support level of $61.02 with a moderate RSI of 37.3.
Transaction History
| SBRA | ▲ Buy | Grant | 791 | $0 | 8/31/2026 | View on chart |
| SBRA | ▲ Buy | Grant | 8,310 | $0 | 6/17/2026 | View on chart |
| SBRA | ▲ Buy | Grant | 817 | $0 | 5/29/2026 | View on chart |
| CATY | ▲ Buy | Grant | 1,593 | $0 | 4/15/2026 | View on chart |
| SBRA | ▲ Buy | Grant | 781 | $0 | 2/27/2026 | View on chart |
| SBRA | ▲ Buy | Grant | 882 | $0 | 11/28/2025 | View on chart |
| SBRA | ▲ Buy | Grant | 887 | $0 | 8/29/2025 | View on chart |
| SBRA | ▲ Buy | Grant | 8,178 | $0 | 6/12/2025 | View on chart |
| SBRA | ▲ Buy | Grant | 815 | $0 | 5/30/2025 | View on chart |
| CATY | ▲ Buy | Grant | 1,913 | $0 | 5/15/2025 | View on chart |
| SBRA | ▲ Buy | Grant | 843 | $0 | 2/28/2025 | View on chart |
| SBRA | ▲ Buy | Grant | 737 | $0 | 11/29/2024 | View on chart |
| SBRA | ▲ Buy | Grant | 793 | $0 | 8/30/2024 | View on chart |
| SBRA | ▲ Buy | Grant | 9,480 | $0 | 6/13/2024 | View on chart |
| SBRA | ▲ Buy | Grant | 719 | $0 | 5/31/2024 | View on chart |
| SBRA | ▲ Buy | Grant | 741 | $0 | 2/29/2024 | View on chart |
| SBRA | ▲ Buy | Grant | 688 | $0 | 11/30/2023 | View on chart |
| SBRA | ▲ Buy | Grant | 783 | $0 | 8/31/2023 | View on chart |
| SBRA | ▲ Buy | Grant | 11,382 | $0 | 6/14/2023 | View on chart |
| SBRA | ▲ Buy | Grant | 554 | $0 | 5/31/2023 | View on chart |
| SBRA | ▲ Buy | Grant | 512 | $0 | 2/28/2023 | View on chart |
| SBRA | ▲ Buy | Grant | 460 | $0 | 11/30/2022 | View on chart |
| SBRA | ▲ Buy | Grant | 389 | $0 | 8/31/2022 | View on chart |
| SBRA | ▲ Buy | Grant | 8,751 | $0 | 6/14/2022 | View on chart |
| SBRA | ▲ Buy | Grant | 224 | $0 | 5/31/2022 | View on chart |
| SBRA | ▲ Buy | Grant | 228 | $0 | 2/28/2022 | View on chart |
| SBRA | ▲ Buy | Grant | 232 | $0 | 11/30/2021 | View on chart |
| SBRA | ▲ Buy | Grant | 184 | $0 | 8/31/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Sabra Health Care REIT analysts lower price targets
UBS kept a neutral rating on Sabra Health Care REIT but reduced its price target to $20. Barclays also maintained an equal‑weight stance while cutting its target to $21. Both revisions suggest a more modest outlook for the REIT. The new targets sit near the stock’s recent support level around $19.70.
Sabra Health Care REIT analysts lower price targets. UBS kept a neutral rating on Sabra Health Care REIT but reduced its price target to $20. Barclays also maintained an equal‑weight stance while cutting its target to $21. Both revisions suggest a more modest outlook for the REIT. The new targets sit near the stock’s recent support level around $19.70.